Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by princeofcuton Jul 28, 2015 5:10pm
141 Views
Post# 23969085

RE:RE:RE:RE:Someone Please Explain

RE:RE:RE:RE:Someone Please Explainthe price of RVX IMO reflects two primary issues:

a) RVX is now a stock that trades with chinee stock market

b) FDA it seems as i read between the lines in the AIF is expecting the traditional 2 PIII trials before approval.

this makes sense and is quite problematic, 2 PIII trials is the SOP of the FDA particularly where there is a SoC.  i am unsure how RVX will get around this issue as the PII trials were relatively lowly powered (not enough patients)...RVX is targeting for BoM i believe 250 events i wonder if they need to be bumping this up if they truly believe in the science and those very strong RRR's, as i suspect the only way to not do 2 PIII's is an overwhelmingly homerun BoM...one issue would be durability of the RRR, do the "tails" converge as time progresses say over 18 months????

ps i believe the US has recently passed some new drug bill which i believe "liberalizes" some of the classic FDA processes..if RVX were smart IMO they wait until that dust settles before finalizing anything (if they can)....

Bullboard Posts